Bone Marrow Transplant volume 51, issue 5, P698-704 2016 DOI: 10.1038/bmt.2015.350 View Full Text
|
|
Share
N Bleyzac, D Cuzzubbo, C Rénard, N Garnier, V Dubois, C Domenech, M-P Goutagny, A Plesa, N Grardel, S Goutelle, A Janoly-Duménil, Y Bertrand

Abstract: There is currently a major concern regarding the optimal immunosuppression therapy to be administered after hematopoietic stem cell transplantation (HSCT) to reduce both the toxicity of GvHD and the rate of relapse. We report the outcome of high-risk leukemia children transplanted with a new way of managing cyclosporine (CsA)-based GvHD prophylaxis. A total of 110 HSCT in 109 ALL or AML children who received CsA without mycophenolate or methotrexate in matched related as well as in matched or mismatched unrel…

expand abstract
Filters

Filter received citations by the textual context, citing paper title, authors, etc.

Citation Types

0
12
0

Paper Sections

0
0
0
0
0

Publication Types

0
0
0
0

Relationship beta

0
0